Neurocrine Biosciences (NBIX) Net Cash Flow (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Net Cash Flow for 17 consecutive years, with $64.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 7.6% year-over-year to $64.4 million; the trailing twelve-month figure through Jun 2026 stood at $67.1 million (down 45.93% YoY), and the FY2025 full-year result was $480.0 million, up 2751.93% from the prior year.
• Net Cash Flow grew to $64.4 million in Q2 2026 per NBIX's latest filing, from -$446.5 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $372.8 million in Q4 2025 and bottomed at -$446.5 million in Q1 2026.
• Historically, Net Cash Flow has averaged -$227777.8 across 5 years, with a median of $50.4 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow jumped 421.93% in 2025, then sank 1047.81% in 2026.
• Over 5 years, Net Cash Flow stood at $52.0 million in 2022, then tumbled by 182.5% to -$42.9 million in 2023, then plunged by 169.93% to -$115.8 million in 2024, then surged by 421.93% to $372.8 million in 2025, then sank by 82.73% to $64.4 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $64.4 million, -$446.5 million, and $372.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.